Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy (Q58199982)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Marco Maccauro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Carlo Chiesa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Luigi Mariani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Claudio Pascali

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Vincenzo Mazzaferro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Filippo de Braud

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Massimo Milione

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Alice Lorenzoni

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Anna Bogni

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Angela Coliva

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Salvatore Lo Vullo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

R Buzzoni

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

E Bombardieri

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

1 February 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Nuclear Medicine and Molecular Imaging

29 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

41

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

223-230

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00259-013-2578-5

29 February 2020

exact match

0 references

cites work

Updated population-based review of carcinoid tumors

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

Therapeutic radiopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

[111In-DTPA-D-Phe1]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling and in vitro validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response--implications for radionuclide therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

Yttrium-90 DOTATOC therapy in GEP-NET and other SST2 expressing tumors: a selected review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-013-2578-5

Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24233003

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24233003

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24233003

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00259-013-2578-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24233003%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference